International Stem Cell Corp., a biotech company focused on therapeutic applications of human parthenogenetic stem cells, today announced that its wholly owned subsidiary Lifeline Cell Technology achieved 35 percent growth in 2011 first-quarter product sales, and gained more than 200 new customers over the year prior.

The company attributes the improvement to more than 30 new product introductions, as well as the development of worldwide distribution channels in Japan, India, Taiwan, South Korea and Singapore.

Lifeline also noted significant progress in its growth strategy, which includes expanding product applications into manufacturing human tissues and cells for clinical use. The company develops, manufactures and markets the Lifeline® brand of cell culture products, and plays a supporting role in ISCO’s long-term strategy to be a leading developer and manufacturer of human cells and human-cell-based products for clinical applications.

Lifeline CEO Jeffrey Janus highlighted the company’s partnership with Cytograft Tissue Engineering, and how it affects ISCO’s business plan.

“… Importantly, we have also moved closer to validating the feasibility of ISCO’s strategic plan as our proprietary FibroLife® media is being used to cultivate tissue-engineered blood vessels for Cytograft Tissue Engineering in Novato, California,” Janus stated.

Lifeline recently moved into new laboratory facilities with cGMP level manufacturing capabilities as it prepares to produce clinical grade products.

For more information visit www.internationalstemcell.com